Early MRFIT studies showed that blood pressure has a significant impact on the prognosis of patients with coronary artery disease, and that the risk of death in patients with coronary artery disease can increase with increased blood pressure. Many previous studies have found that antihypertensive treatment can clearly reduce the risk of ischemic heart disease (heart attack plus coronary heart disease death). Although controlling hypertension is the key to preventing and treating cardiovascular disease, the blood pressure compliance rate of patients with coronary heart disease in China is low. There is a big gap between the ideal blood pressure lowering level and the standard. In recent years, various guidelines have elaborated on the antihypertensive targets and drug recommendations for such patients, but the debate on blood pressure target values in the field of antihypertensive has never stopped. The 2007 European hypertension guidelines recommend that blood pressure should be lowered to at least 130/80 mmHg in high-risk/very high-risk patients with hypertension combined with diabetes or coronary artery disease, but most studies have found that patients with coronary artery disease do not benefit more when their blood pressure is lowered to 130/80 mmHg, so this target value has been discussed by scholars at home and abroad. The INVEST study found that the risk of cardiovascular disease in patients with hypertension combined with coronary artery disease decreased with lower blood pressure, but increased when diastolic blood pressure was reduced to 70 mmHg, and the TNT study also found a U-shaped curve between diastolic blood pressure and cardiovascular events (at 70 mmHg). The TNT study also found a U-shaped curve (with 70 mmHg as the turning point) between diastolic blood pressure and cardiovascular events; the ONTARGET study showed a J-shaped curve between systolic blood pressure and cardiovascular events, i.e., cardiovascular risk increased rather than decreased in diabetic patients with atherosclerotic disease or with target organ damage when systolic blood pressure was reduced to 130 mmHg. The 2009 ESH European guidelines for hypertension recommend a BP target of 130-139/80-85 mmHg for this high-risk group, as there is no difference in the occurrence of endpoint events between the group with strict BP control and the group with conventional BP control, and the former group has an increased risk of death. The 2015 Taiwan hypertension guidelines recommend that blood pressure should be lowered to 130/80 mmHg in Asian high-risk groups, while the European and American guidelines recommend 140/90 mmHg, and recommend that physicians make appropriate adjustments based on their own experience and individual patient conditions. The 2010 Chinese guidelines for the prevention and treatment of hypertension recommend that the target value for lowering blood pressure in patients with coronary artery disease combined with hypertension is <130/80 mmHg, while emphasizing individualized treatment; patients with severe coronary artery disease or those aged >65 years should try to maintain diastolic blood pressure at 60 mmHg to ensure cardiac blood supply. AHA/ACC/ASH recommendations for BP target values in patients with coronary artery disease combined with hypertension The joint guideline recommends a BP target value of 140/90 mmHg in patients with stable angina (I, A), and lower BP target values (130/80 mmHg) may be considered in some patients with coronary artery disease, history of stroke or TIA, or critical illnesses such as coronary artery disease (IIb, B); for patients with ACS, the The guideline recommends a target value of 140/90 mmHg (IIa, C), and a reduction to 130/80 mmHg at discharge is also a reasonable option (IIb, C); for patients with ischemic heart failure, the target value is 140/90 mmHg, with some patients considered for reduction to 130/80 mmHg. The composition of cardiovascular events in Chinese hypertensive patients differs from that in Western populations, with stroke events predominating (about The clinical situation of patients with coronary artery disease is complex and individualized treatment plans should be developed according to the guidelines.